Abstract:Background: Ventricular septal defect (VSD) is the most common congenital cardiac malformation, accounting for approximately 30% of congenital heart defects. Conventional surgical repair using cardiopulmonary bypass is invasive and associated with morbidities and prolonged hospital stay. With the advent of interventional approaches and availability of different occluding devices, the technique of perventricular device closure is evolving and being implemented successfully in larger groups of patients. We present herein, our initial experience of perventricular device closure for the ventricular septal defects in children to assess risks and benefits. Methods: From March, 2023 to February, 2024, we have performed perventricular closure of ventricular septal defects in 13 children, under guidance of transesophageal echocardiography without cardiopulmonary bypass support. The median age at operation was 2 year (range 1.3-10 years) with the median body weight 11 kg (range 8.7-16.6 kg). Sixty-nine percent were males. The ventricular septal defect sizes ranged from 2.7 to 6 mm (mean 4.7 mm). Seven defects were perimembranous, four sub-aortic and two were muscular. One patient also underwent pulmonary artery de-banding with pulmonary artery balloon angioplasty and other one patent ductus arteriosus ligation, concomitantly. For defect closure, we used ventricular septal defect occlusion device (MemoPart™, Lepu Medical Technology Company, China) through a 3-cm skin incision in the lower- third of the sternum. The device sizes ranged from 5 to 8 mm (mean 6.9+-1.8 mm) and all patients except for two required symmetrical devices. Results: All patients underwent device closure successfully. The procedural duration ranged between 32 and 52 min. None of the patients required cardiopulmonary bypass. The mean ventilation time and intensive care unit stay was 3 and 24 h, respectively. None of the patients required inotropic support or blood transfusions. Moreover, no patients developed any arrhythmias including heart block. The average length of hospital stay was 4.4 days. At the latest follow up, there were no residual shunts, conduction disturbances, device dislodgement or major aortic or tricuspid valve complications seen in any patients. There was no mortality. Conclusions: Perventricular device closure of ventricular septal defects is a less invasive, extremely safe and effective method in children. It is associated with very fast recovery, shorter hospitalization time and better cosmetic incision. Moreover, it avoids cardiopulmonary bypass. The modifications and refinements in the design, material and implantation techniques will help in expanding the indications and prevent complications in the long-term.

Transcatheter patent ductus arteriosus closure in premature infants requiring high-frequency ventilation

Minimally Invasive Experiences on Perventricular Device Closure of Ventricular Septal Defects in Children

Transcatheter patent arterial duct closure in premature infants: A new technique to ease access to the patent arterial duct, with particular benefit for the tricuspid valve

Transcatheter Closure of Patent Ductus Arteriosus in Preterm Ventilation-Dependent Neonates: A Case Series Report.

Minimally Invasive Perventricular Device Closure of Perimembranous Ventricular Septal Defect Without Cardiopulmonary Bypass: Multicenter Experience and Mid-Term Follow-Up

Perimembranous Ventricular Septal Defect Performed Super Minimally Invasive Trans Intercostal Device Closure under the Guidance of Transesophageal Echocardiography in Children

Efficacy of arterial duct stenting in neonatal pulmonary atresia with intact ventricular septum]

Procedural closure of the patent ductus arteriosus in preterm infants: a clinical practice guideline

Patent Ductus Arteriosus Closure Using the New Amplatzer Duct Occluder. Preliminary Results and Review of the Literature.

Mobile bedside ductus arteriosus closure in severely premature neonates using only echocardiographic guidance

Patent ductus arteriosus closure in small infants weighing less than 1500 g using KA micro plug: steps and tips

Percutaneous closure of patent ductus arteriosus in premature infants: A French national survey: A Titanic movement in technology and technique- Beware the icebergs!

Transcatheter and Surgical Ductus Arteriosus Closure in Very Low Birth Weight Infants: 2018-2022

Impact of a Multidisciplinary Service Line and Program for Transcatheter Device Closure of the Neonatal Ductus Arteriosus

Cardiorespiratory Instability after Percutaneous Patent Ductus Arteriosus Closure: A Multicenter Cohort Study

Transcatheter Closure of Patent Ductus Arteriosus in Infants With Weight Under 1,500 Grams

Percutaneous closure of patent ductus arteriosus versus surgical treatment in low-birth-weight preterms: a systematic review and meta-analysis

Perventricular device closure of the ventricular septal defects in children-first experience in the United Arab Emirates

[Transcatheter Occlusion of Patent Ductus Arteriosus in a Preterm Infant and Review of Literatures].

A Safe Technique for Closure of Patent Ductus Arteriosus in Adult Patients

[Transcatheter Closure for Patent Ductus Arteriosus in Children].